Axonics, Inc. (NASDAQ:AXNX) Holdings Trimmed by Peregrine Capital Management LLC

Peregrine Capital Management LLC lowered its stake in Axonics, Inc. (NASDAQ:AXNX - Free Report) by 14.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 169,629 shares of the company's stock after selling 29,234 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.33% of Axonics worth $10,556,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Invesco Ltd. lifted its stake in Axonics by 5.8% in the 3rd quarter. Invesco Ltd. now owns 1,634,984 shares of the company's stock valued at $91,755,000 after buying an additional 90,132 shares in the last quarter. Algert Global LLC purchased a new stake in Axonics in the 3rd quarter valued at approximately $1,313,000. Hedges Asset Management LLC raised its holdings in Axonics by 6.5% in the 4th quarter. Hedges Asset Management LLC now owns 8,600 shares of the company's stock valued at $535,000 after acquiring an additional 525 shares during the last quarter. Mackenzie Financial Corp acquired a new position in Axonics in the 3rd quarter valued at $68,499,000. Finally, Jennison Associates LLC raised its holdings in Axonics by 12.2% in the 3rd quarter. Jennison Associates LLC now owns 225,957 shares of the company's stock valued at $12,681,000 after acquiring an additional 24,631 shares during the last quarter. Hedge funds and other institutional investors own 99.48% of the company's stock.

Axonics Stock Up 0.0 %

Shares of AXNX stock traded up $0.03 on Tuesday, reaching $67.75. 671,206 shares of the stock were exchanged, compared to its average volume of 1,351,352. Axonics, Inc. has a 1-year low of $47.59 and a 1-year high of $69.68. The stock has a market cap of $3.46 billion, a P/E ratio of -521.11 and a beta of 0.56. The firm has a 50 day moving average of $68.10 and a two-hundred day moving average of $61.88.

Axonics (NASDAQ:AXNX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.07. Axonics had a negative return on equity of 1.00% and a negative net margin of 1.66%. The firm had revenue of $109.70 million during the quarter, compared to the consensus estimate of $107.33 million. During the same period in the prior year, the firm earned $0.01 EPS. The firm's quarterly revenue was up 27.7% compared to the same quarter last year. On average, equities research analysts predict that Axonics, Inc. will post 0.32 EPS for the current fiscal year.

Insider Activity at Axonics

In other Axonics news, EVP John Woock sold 15,899 shares of the company's stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total value of $1,076,998.26. Following the completion of the transaction, the executive vice president now directly owns 77,403 shares of the company's stock, valued at approximately $5,243,279.22. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Axonics news, CFO Kari Leigh Keese sold 3,489 shares of the company's stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total value of $236,344.86. Following the completion of the transaction, the chief financial officer now directly owns 43,323 shares of the company's stock, valued at approximately $2,934,700.02. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP John Woock sold 15,899 shares of the company's stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total transaction of $1,076,998.26. Following the completion of the transaction, the executive vice president now directly owns 77,403 shares of the company's stock, valued at $5,243,279.22. The disclosure for this sale can be found here. In the last three months, insiders sold 65,837 shares of company stock worth $4,459,798. Corporate insiders own 1.85% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on AXNX. Truist Financial reiterated a "hold" rating and issued a $71.00 price target (down from $73.00) on shares of Axonics in a report on Friday, January 12th. Needham & Company LLC reiterated a "hold" rating on shares of Axonics in a report on Wednesday, January 17th. SVB Leerink reiterated a "market perform" rating and issued a $71.00 price target on shares of Axonics in a report on Friday, January 12th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $71.00 price target (up from $68.00) on shares of Axonics in a report on Wednesday, January 10th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $71.00 price target (down from $75.00) on shares of Axonics in a report on Friday, January 12th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $70.73.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.